Payment overview · 2025
General Payments
$532.20
26 reported records · 12 companies
Healthcare provider profile · identity verified
Eric Charles Johnson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MOBILE, AL · NPI 1902812803
Verified facts
What the public records show
CMS Open Payments records show Eric Charles Johnson, M.D. received $532.20 in general payments during 2025 across 26 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $89.99 | 16.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.72 | 15.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.35 | 10.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.09 | 10.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.65 | 9.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.40 | 9.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.09 | 8.3% | 2 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $29.96 | 5.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.12 | 3.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.16 | 3.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.12 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.55 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $532.20 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $89.99 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.35 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $57.35 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.65 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.65 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.40 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.91 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.91 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.81 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.67 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.67 | 2 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $29.96 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $29.96 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 135 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 147 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 202 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
98 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
135 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
147 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
202 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
187 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 990 | 320 |
| Atorvastatin Calcium | Atorvastatin Calcium | 979 | 313 |
| Gabapentin | Gabapentin | 776 | 152 |
| Pantoprazole Sodium | Pantoprazole Sodium | 742 | 241 |
| Levothyroxine Sodium | Levothyroxine Sodium | 591 | 168 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 533 | 167 |
| Losartan Potassium | Losartan Potassium | 497 | 147 |
| Lisinopril | Lisinopril | 481 | 151 |
| Zolpidem Tartrate | Zolpidem Tartrate | 466 | 59 |
| Trazodone Hcl | Trazodone Hcl | 447 | 123 |
| Metformin Hcl | Metformin Hcl | 446 | 143 |
| Omeprazole | Omeprazole | 443 | 134 |
| Pregabalin | Pregabalin | 358 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 352 | 107 |
| Pravastatin Sodium | Pravastatin Sodium | 337 | 107 |
| Meloxicam | Meloxicam | 330 | 115 |
| Furosemide | Furosemide | 326 | 123 |
| Allopurinol | Allopurinol | 317 | 105 |
| Escitalopram Oxalate | Escitalopram Oxalate | 317 | 95 |
| Carvedilol | Carvedilol | 270 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 267 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 83 |
| Tizanidine Hcl | Tizanidine Hcl | 258 | 69 |
| Montelukast Sodium | Montelukast Sodium | 253 | 77 |
| Famotidine | Famotidine | 238 | 73 |
| Potassium Chloride | Potassium Chloride | 238 | 84 |
| Ezetimibe | Ezetimibe | 237 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 222 | 75 |
| Ozempic | Semaglutide | 202 | 44 |
| Metformin Hcl Er | Metformin Hcl | 192 | 71 |
| Pioglitazone Hcl | Pioglitazone Hcl | 191 | 62 |
| Eliquis | Apixaban | 187 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 186 | 141 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 68 |
| Naproxen | Naproxen | 182 | 58 |
| Ibuprofen | Ibuprofen | 180 | 65 |
| Tramadol Hcl | Tramadol Hcl | 179 | 58 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 172 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 56 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 159 | 51 |
| Sertraline Hcl | Sertraline Hcl | 155 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 150 | 58 |
| Mounjaro | Tirzepatide | 147 | 24 |
| Alendronate Sodium | Alendronate Sodium | 145 | 50 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 145 | 48 |
| Prednisone | Prednisone | 144 | 105 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 42 |
| Farxiga | Dapagliflozin Propanediol | 135 | 26 |
| Glimepiride | Glimepiride | 132 | 42 |
| Celecoxib | Celecoxib | 125 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 120 | 33 |
| Meclizine Hcl | Meclizine Hcl | 119 | 46 |
| Simvastatin | Simvastatin | 118 | 33 |
| Doxazosin Mesylate | Doxazosin Mesylate | 113 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 25 |
| Jardiance | Empagliflozin | 98 | 23 |
| Linzess | Linaclotide | 98 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 96 | 63 |
| Temazepam | Temazepam | 94 | 11 |
| Clonazepam | Clonazepam | 92 | 17 |
| Valsartan | Valsartan | 92 | 31 |
| Donepezil Hcl | Donepezil Hcl | 91 | 35 |
| Mometasone Furoate | Mometasone Furoate | 90 | 43 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 87 | 22 |
| Buspirone Hcl | Buspirone Hcl | 85 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 28 |
| Bupropion Xl | Bupropion Hcl | 84 | 27 |
| Mirtazapine | Mirtazapine | 83 | 27 |
| Valacyclovir | Valacyclovir Hcl | 83 | 35 |
| Spironolactone | Spironolactone | 82 | 23 |
| Doxepin Hcl | Doxepin Hcl | 81 | 27 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 78 | 26 |
| Testosterone Cypionate | Testosterone Cypionate | 77 | 11 |
| Fluconazole | Fluconazole | 76 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 27 |
| Promethazine Hcl | Promethazine Hcl | 74 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 24 |
| Trulicity | Dulaglutide | 74 | 13 |
| Azithromycin | Azithromycin | 72 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 47 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 36 |
| Aripiprazole | Aripiprazole | 65 | 12 |
| Diazepam | Diazepam | 65 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 64 | suppressed |
| Atenolol | Atenolol | 63 | 20 |
| Colchicine | Colchicine | 63 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 63 | 23 |
| Fenofibrate | Fenofibrate | 63 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 19 |
| Mupirocin | Mupirocin | 63 | 38 |
| Nifedipine Er | Nifedipine | 63 | 20 |
| Amoxicillin | Amoxicillin | 62 | 48 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 46 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 17 |
| Xarelto | Rivaroxaban | 58 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 19 |
| Tradjenta | Linagliptin | 56 | suppressed |
| Chlorthalidone | Chlorthalidone | 55 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 42 |
| Estradiol | Estradiol | 54 | 13 |
| Glipizide | Glipizide | 52 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 46 | 14 |
| Ondansetron Odt | Ondansetron | 46 | 24 |
| Topiramate | Topiramate | 46 | 16 |
| Lorazepam | Lorazepam | 45 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 18 |
| Gemfibrozil | Gemfibrozil | 44 | suppressed |
| Nystatin | Nystatin | 44 | 24 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 43 | 11 |
| Myrbetriq | Mirabegron | 43 | 13 |
| Sucralfate | Sucralfate | 43 | 20 |
| Azelastine Hcl | Azelastine Hcl | 42 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | 12 |
| Clonidine Hcl | Clonidine Hcl | 39 | 11 |
| Levemir Flexpen | Insulin Detemir | 39 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 17 |
| Cephalexin | Cephalexin | 37 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 17 |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Ramipril | Ramipril | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Torsemide | Torsemide | 28 | 14 |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 23 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | 15 |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 21 |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Olanzapine | Olanzapine | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 15 |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $532.20 · 26 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, EGRIFTA, FARXIGA, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, Symbravo, TROGARZO, UBRELVY, VRAYLAR, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error